1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2010
-
Mark
Diagnostik och uppföljning av patienter med små M-komponenter. Med sikte på att undvika transformation till malign sjukdom.
(
- Contribution to journal › Scientific review
-
Mark
Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? - response
(
- Contribution to journal › Letter
-
Mark
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article
- 2009
-
Mark
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
(
- Contribution to journal › Article
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
(
- Contribution to journal › Article
-
Mark
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
(
- Contribution to journal › Article